Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The ENVB news feed on Stock Titan aggregates company-issued press releases and other public updates so readers can follow how Enveric describes the progress of its pipeline, intellectual property estate, and capital markets activity.
Recent news from Enveric highlights several recurring themes. The company frequently reports on patent issuances and notices of allowance from the United States Patent and Trademark Office, including patents covering fused heterocyclic mescaline derivatives and N‑heterocycle substituted tryptamine derivatives within its EVM301 and EVM401 series. These announcements emphasize Enveric’s efforts to expand its portfolio of neuroplastogenic, non-hallucinogenic molecules and to strengthen composition of matter protection for potential treatments of neuropsychiatric and addiction disorders.
Another key category of ENVB news involves pipeline and preclinical development for the lead candidate EB‑003. Company updates have discussed preclinical models in post-traumatic stress disorder, dose range finding studies, chemistry and manufacturing work, and interactions with the U.S. Food and Drug Administration related to a planned Investigational New Drug submission. These items provide insight into how Enveric portrays the advancement of EB‑003 toward potential first-in-human studies.
Enveric also issues news related to financing and listing matters, such as warrant exercise inducement transactions, gross proceeds from warrant exercises, and actions taken in connection with Nasdaq listing requirements, including a reverse stock split. For investors and observers, these releases give context on how the company funds its operations and addresses exchange compliance.
By reviewing ENVB news on Stock Titan, readers can monitor Enveric’s own descriptions of its scientific progress, patent estate, financing transactions, and corporate developments over time. Investors who follow early-stage biotechnology companies may choose to consult these updates alongside the company’s SEC filings for a fuller view of the risks and plans Enveric outlines in its public communications.
Enveric Biosciences (NASDAQ: ENVB) has announced that its subsidiary, Akos Biosciences, has entered into two licensing agreements with Restoration Biologics for cannabinoid-COX-2 conjugate compounds. The agreements cover both pharmaceutical and non-pharmaceutical applications for human and animal use, primarily focusing on joint pathologies like osteoarthritis and rheumatoid arthritis.
The exclusive, global licenses grant Restoration Biologics full development, marketing, and commercialization rights. The agreements include potential milestone payments totaling $61 million for the pharmaceutical license and $21 million for the non-pharmaceutical license. Royalty rates range from low single digit to low double digits on future sales, contingent on meeting specific sales criteria.
Enveric Biosciences (NASDAQ: ENVB) has completed its previously announced public offering, raising $5 million in gross proceeds. The offering consisted of 1,666,666 shares of common stock (or equivalents) and two series of warrants at a combined price of $3.00 per share.
The offering included Series A warrants expiring in five years and Series B warrants expiring in eighteen months, both with a $3.00 exercise price. H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the proceeds for product development, working capital, and general corporate purposes.
The offering was conducted under a Form S-1 registration statement declared effective by the SEC on January 30, 2025.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics, has announced the pricing of a $5 million public offering. The offering includes 1,666,666 shares of common stock (or equivalents) with Series A and Series B warrants, priced at $3.00 per share.
Each share comes with one Series A warrant (5-year expiration) and one Series B warrant (18-month expiration), both with a $3.00 exercise price. The offering is expected to close around February 3, 2025, with H.C. Wainwright & Co. acting as exclusive placement agent. The company plans to use the proceeds for product development, working capital, and general corporate purposes.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics for anxiety, depression, and addiction disorders, has announced its participation in two major industry events during 'J.P. Morgan Week 2025' in San Francisco.
CEO Joseph Tucker, Ph.D., will participate in a panel discussion on 'Future of Psychedelics' and deliver a presentation at the Sachs Associates 8th Annual Neuroscience Innovation Forum on January 12, 2025. The panel discussion is scheduled for 2:20 p.m. PDT, followed by the presentation at 4:05 p.m. PDT at the Marines' Memorial Club.
Additionally, the company will attend Biotech Showcase 2025 from January 13-15, 2025, at the Hilton San Francisco Union Square. During both events, Enveric's management team will conduct one-on-one meetings with registered investors and potential partners to discuss their business strategy, recent achievements, and upcoming milestones.
Sinclair has announced that 'The Triple Option' podcast will broadcast live from the Army-Navy Game Media Row presented by USAA on December 13, 2024, from 12-1:30pm ET. The special broadcast, hosted by Urban Meyer, Mark Ingram II, and Rob Stone, will take place at the Military Women's Memorial in Arlington National Cemetery. USAA CEO Wayne Peacock will be a featured guest on the show.
The live broadcast will be available on the podcast's YouTube, X, and Facebook platforms (@3xoptionshow), with an on-demand version available later. USAA will maintain a strong presence across Sinclair's owned/operated station websites throughout December, with the partnership developed in collaboration with Publicis Lion Company.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on neuroplastogenic therapeutics, announced the issuance of two U.S. patents (Nos. 12,133,856 and 12,138,276) for its EVM301 series molecules, bringing the total to 11 patents. These patents cover novel psilocybin derivative compounds and their pharmaceutical formulations. Enveric's lead candidate, EB-003, targets anxiety, depression, and addiction disorders, showing potential for promoting neuroplasticity without hallucinogenic effects. Additionally, two other patents (Nos. 12,065,404 and 12,077,498) were issued for EVM201 series prodrugs, protecting novel tryptamine derivatives. Enveric has licensed its EVM201 series to MycoMedica Life Sciences and announced out-licensing deals with MycoMedica and Aries Science & Technology, positioning Enveric to focus on EB-003 development and establish potential future income streams.
Enveric Biosciences (NASDAQ: ENVB) announced positive results from preclinical pharmacokinetic studies of EB-003, demonstrating favorable oral bioavailability and brain penetration without hallucination-like behavior in rat and dog models. The studies showed dose-proportional oral bioavailability and a significant brain/plasma ratio of 5-6 in rats, higher than previously observed in mice (~1.5). No clinical signs of hallucination were observed in either species. The company plans to submit an Investigational New Drug (IND) application to the FDA in the second half of 2025 for this potential treatment of depression, anxiety, and other psychiatric disorders.
Enveric Biosciences (NASDAQ: ENVB) reported Q3 2024 financial results and corporate updates. The company made progress with EB-003, its lead neuroplastogenic molecule for mental health disorders, confirming oral bioavailability and brain exposure in preclinical studies. The company reported a net loss of $2.1 million ($0.24 per share) compared to $2.8 million ($1.30 per share) in Q3 2023. Cash-on-hand was $3.1 million. Enveric secured licensing agreements with Aries Science & Technology for radiation dermatitis treatment and with MycoMedica Life Sciences for EB-002. The company plans to submit an IND application for EB-003 in H2 2025.
Enveric Biosciences (NASDAQ: ENVB) has signed a licensing agreement with MycoMedica Life Sciences for its EVM201 program, including drug candidate EB-002, a synthetic prodrug for treating neuropsychiatric disorders. The agreement includes potential milestone payments up to $62 million plus tiered single-digit royalties on future sales. MycoMedica receives exclusive global rights and will assume responsibility for all development phases. This strategic move allows Enveric to focus on advancing EB-003, their novel non-hallucinogenic neuroplastogen drug candidate, while maintaining potential future revenue streams from EB-002. The company plans to file an Investigational New Drug application for EB-003 in 2025.
Enveric Biosciences (NASDAQ: ENVB) announces the expansion of patent protection for its EVM301 portfolio through five new US patents and three patent application allowances. The company now holds nine total US patents covering its drug candidate library. The patents cover various tryptamine derivative molecules, including carboxylated, aminated, prenylated, glycosylated, nitrilated, and halogenated derivatives. The company's lead candidate, EB-003, targeting treatment-resistant depression and anxiety, is in preclinical development with planned IND filing in 2025. The compound shows potential for promoting neuroplasticity without inducing hallucinations.